drugset / Trial / NCT00411372

Shortness Of Breath Questionnaire Validation Study

NCT00411372

Phase 3 Withdrawn GlaxoSmithKline
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will last for approximately 8 weeks and will involve 4 visits. The study is being carried out to validate a shortness of breath questionnaire

Timeline

Start
2006-11
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone propionate Other / unclassified 0.25 mg
Subject Salmeterol Other / unclassified 0.05 mg